Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
MedImmune LLC |
---|---|
Information provided by: | MedImmune LLC |
ClinicalTrials.gov Identifier: | NCT00192452 |
Condition | Intervention | Phase |
---|---|---|
Psoriasis |
Drug: MEDI-507 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment |
Official Title: | A Phase II Randomized, Double-Blind, Placebo-Controlled Study of MEDI-507, a Humanized Monoclonal Antibody That Binds to the CD2 Receptor, Administered by Intravenous Infusion to Adults With Plaque Psoriasis |
Estimated Enrollment: | 120 |
Study Start Date: | March 2001 |
Estimated Study Completion Date: | December 2001 |
Ages Eligible for Study: | 18 Years to 64 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
MDS Pharma Services (US) Inc. | |
Phoenix, Arizona, United States, 85044 | |
United States, North Carolina | |
Wake Forest University School of Medicine | |
Winston-Salem, North Carolina, United States, 27157 | |
United States, Washington | |
Northwest Kinetics | |
Tacoma, Washington, United States, 98403 |
Study Director: | Stanley Pillemer, MD | MedImmune LLC |
Study ID Numbers: | MI-CP074 |
Study First Received: | September 13, 2005 |
Last Updated: | October 23, 2006 |
ClinicalTrials.gov Identifier: | NCT00192452 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Antibodies, Monoclonal Antibodies Skin Diseases |
Psoriasis Skin Diseases, Papulosquamous Immunoglobulins |
Skin Diseases Psoriasis Skin Diseases, Papulosquamous |